Company Encyclopedia
View More
name
Puma BioTech
PBYI.US
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks.
1.946 T
PBYI.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking43/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE39.69%A
    • Profit Margin17.44%A
    • Gross Margin77.65%A
  • Growth ScoreD
    • Revenue YoY-12.96%E
    • Net Profit YoY59.11%B
    • Total Assets YoY-8.09%E
    • Net Assets YoY62.15%A
  • Cash ScoreD
    • Cash Flow Margin573.30%C
    • OCF YoY-12.96%E
  • Operating ScoreA
    • Turnover1A
  • Debt ScoreC
    • Gearing Ratio43.18%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Puma Biotechnology (NASDAQ:PBYI) Director Michael Patrick Miller Sells 20,000 Shares

    Puma Biotechnology Director Michael Patrick Miller sold 20,000 shares at $4.86 each, totaling $97,200, reducing his ownership by 27.03%. Post-sale, he owns 54,000 shares valued at $262,440. The transaction was disclosed in an SEC filing. Puma's stock has a market cap of $250.09 million, with recent earnings surpassing expectations. Institutional investors hold 61.29% of the stock. Analysts have downgraded the stock from 'strong-buy' to 'buy' and 'hold.'

    Market Beat·
    US
    PBYI
    +1.93%
    Market Beat·
    US
    PBYI
    +1.93%

    Director’s Bold Move: Major Stock Sale at Puma Biotechnology!

    Director Michael Patrick Miller sold 20,000 shares of Puma Biotechnology (PBYI) for $97,200 on November 13, 2025. Puma's recent earnings report shows increased U.S. sales of NERLYNX but declining royalty revenues and new prescriptions, especially in China. Clinical trials, including ALISCA-Breast1, are progressing well. The company updated its revenue and net income estimates. Analysts have mixed views, with Spark rating PBYI as Neutral due to financial improvements and challenges in revenue consistency.

    Tip Ranks·
    US
    PBYI
    +1.93%
    Tip Ranks·
    US
    PBYI
    +1.93%

    Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS

    Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.21 EPS, exceeding estimates of $0.09 by $0.12. The company generated revenue of $54.48 million, surpassing the expected $51.00 million. Puma's return on equity was 53.15% with a net margin of 20.38%. The stock traded up to $5.99, with a market cap of $301.72 million. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a price target of $7.00. Institutional investors hold 61.29% of the stock.

    Market Beat·
    US
    PBYI
    +1.93%
    Market Beat·
    US
    PBYI
    +1.93%

    Puma BioTech | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 54.48 B

    LB filings·
    US
    PBYI
    +1.93%
    LB filings·
    US
    PBYI
    +1.93%

    Puma BioTech | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 54.5 M

    LB filings·
    US
    PBYI
    +1.93%
    LB filings·
    US
    PBYI
    +1.93%
    © 2025 Longbridge｜Disclaimer